High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction

High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction

Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). Early prediction of adverse effects based on the pharmacokinetics of afatinib enables support for quality of life (QOL)...

Full description

Bibliographic Details
Main Authors: Takayuki Takahashi, Hideyuki Terazono, Takayuki Suetsugu, Hideki Sugawara, Junko Arima, Mina Nitta, Toru Tanabe, Kayu Okutsu, Ryuji Ikeda, Keiko Mizuno, Hiromasa Inoue, Yasuo Takeda
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
afatinib
epidermal growth factor receptor
tyrosine kinase inhibitor
non-small-cell lung cancer
trough plasma concentration
receiver operating characteristic curve
Online Access:https://www.mdpi.com/2072-6694/13/14/3425

Internet

https://www.mdpi.com/2072-6694/13/14/3425

Similar Items